Autores: Taberner, E.; Ruiz, M. C.; Saün, X.; Woodward, M.; Montbrau, C.

The main objective of this study was to evaluate the safety and serological response of ERAVAC® (HIPRA, Spain), an inactivated vaccine for preventing the new variant of rabbit haemorrhagic disease virus (RHDV-2), when administered into dwarf pet rabbits.

This study showed that vaccination against RHDV-2 with the licenced vaccine ERAVAC® given to 30- day-old toy dwarf rabbits generates in a low rate transient local signs, while no general signs or important rectal temperature fluctuations were observed. All vaccinated animals responded serologically to ERAVAC® vaccination inducing high antibody response compared to the negative response in the control group.